# Four Routes to the Same Pituitary Cell

> Compare the Growth Hormone Axis Peptides — Peptide Pros USA — Sermorelin, ipamorelin, CJC-1295, and CJC-1295/ipamorelin compared: receptor mechanism, evidence maturity, regulatory status, and what each is studied for.

**GROWTH HORMONE AXIS RESEARCH / COMPARE**

Sermorelin, ipamorelin, CJC-1295, and the CJC-1295/ipamorelin combination, compared on mechanism, evidence maturity, and what each was actually studied for.

## The short version

All four compounds on this desk push the pituitary gland to release its own growth hormone, but they differ in which receptor they use, how long a single dose lasts, and how much controlled human evidence backs them up. Sermorelin has an FDA approval history and the deepest range of human trial doses; ipamorelin has the thinnest human evidence and a failed Phase 2 primary endpoint; CJC-1295 stretches the same GHRH mechanism across days; and the CJC-1295/ipamorelin combination has never been tested as a fixed blend at all. This page lines the four up so the differences are explicit rather than assumed.

## Receptor and mechanism

Sermorelin and CJC-1295 both bind the **GHRH receptor** on pituitary somatotrophs, activating the cAMP/PKA pathway. Sermorelin is the unmodified GHRH(1-29) fragment; CJC-1295 carries four stability-conferring substitutions and, in its DAC form, a covalent albumin-binding linker. Ipamorelin instead binds **GHS-R1a**, the ghrelin receptor, through a Gq/calcium pathway — a mechanism distinct from the GHRH arm. The CJC-1295/ipamorelin combination activates both receptors on the same cell, which co-activation studies in transfected cells suggest can roughly double the cAMP response versus GHRH-receptor activation alone [20].

## Duration of a single dose

This is where the four differ most. Ipamorelin produces a single, short GH pulse — human pharmacokinetic modeling puts its terminal half-life at about 2 hours, with the GH response peaking roughly 40 minutes after dosing [11]. Sermorelin's own IV pharmacokinetic data show GH elevated for about 3 hours despite rapid plasma clearance [6]. CJC-1295 without DAC behaves similarly to sermorelin in duration. CJC-1295 with DAC is the outlier: a single dose raised GH for 6 or more days and IGF-1 for 9 to 11 days in one trial, with an estimated half-life of 5.8 to 8.1 days [15].

## Regulatory and evidence status

| Compound | FDA history | Human trial evidence |
|---|---|---|
| Sermorelin | Previously approved (Geref, NDA 020443); withdrawn 2008 for commercial reasons | Multiple controlled human trials across decades, including pediatric growth and older-adult dosing studies [2][5][6][7] |
| Ipamorelin | Never approved; removed from interim 503A Category 2 in 2024 after nominator withdrawal; reviewed at the Oct. 2024 PCAC meeting | One Phase 2 RCT (missed primary endpoint) plus a single-dose human PK/PD study [10][11] |
| CJC-1295 | Never approved; flagged for immunogenicity concerns in 2024 PCAC briefing materials | Small pharmacology studies in healthy adults; no Phase 3 program [14][15][16] |
| CJC-1295/Ipamorelin | Neither component approved | No trial of the fixed combination; evidence is inferred from each component plus receptor cross-talk data [20] |

Only sermorelin carries a genuine approval history. The other three sit entirely in research-chemical territory, and the combination has the thinnest direct evidence of all, because it has never itself been the subject of a trial.

## What each is studied for

Sermorelin's trial record centers on pediatric growth hormone deficiency and reversing age-related declines in GH and IGF-1 in older adults [5][7]. Ipamorelin's strongest human data point is a postoperative-ileus trial that did not show a significant benefit [10], alongside preclinical work on chemotherapy-associated weight loss [8] and bone growth in rats [12]. CJC-1295's studies focus narrowly on GH/IGF-1 pharmacodynamics and pulsatility preservation in healthy adults [15][16]. The combination has no dedicated trials; the closest supporting data is a 2026 meta-analysis of the related GHRH analog tesamorelin, showing body-composition benefit with a favorable short-term safety profile [17], and a class-wide secretagogue safety review [18].

## The shared caution

Every compound on this desk shares the same underlying mechanistic caution: raising growth hormone and IGF-1, whether through the GHRH receptor or the ghrelin receptor, is theorized to carry some long-term cancer-related risk because both hormones can promote cell growth — a concern that applies across the whole class and has not been resolved by long-term human data for any of the four [1][3]. All four are prohibited in sport at all times under WADA Section S2, and research-grade material from unregulated suppliers carries no pharmaceutical quality assurance regardless of which compound is involved.

---

A clinician's-briefing read of the Growth Hormone Axis literature — findings and citations, never a protocol.